Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine.
Autor(a) principal: | |
---|---|
Data de Publicação: | 2007 |
Outros Autores: | , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFOP |
Texto Completo: | http://www.repositorio.ufop.br/handle/123456789/1042 |
Resumo: | In order to assess the immunotherapeutic potential on canine visceral leishmaniasis of the Leishmune ® vaccine, formulated with an increased adjuvant concentration (1 mg of saponin rather than 0.5 mg), 24 mongrel dogs were infected with Leishmania (L.) chagasi . The enriched-Leishmune ® vaccine was injected on month 6, 7 and 8 after infection, when animals were seropositive and symptomatic. The control group were injected with a saline solution. Leishmune ® -treated dogs showed significantly higher levels of anti-FML IgG antibodies (ANOVA; p < 0.0001), a higher and stable IgG2 and a decreasing IgG1 response, pointing to a TH1 T cell mediated response. The vaccine had the following effects: it led to more positive delayed type hypersensitivity reactions against Leishmania lysate in vaccinated dogs (75%) than in controls (50%), to a decreased average of CD4+ Leishmania -specific lymphocytes in saline controls (32.13%) that fell outside the 95% confidence interval of the vaccinees (41.62%, CI95% 43.93–49.80) and an increased average of the clinical scores from the saline controls (17.83) that falls outside the 95% confidence interval for the Leishmune ® immunotherapy-treated dogs (15.75, CI95% 13.97–17.53). All dogs that received the vaccine were clustered, and showed lower clinical scores and normal CD4+ counts, whereas 42% of the untreated dogs showed very diminished CD4+ and higher clinical score. The increase in clinical signs of the saline treated group was correlated with an increase in anti-FML antibodies (p < 0.0001), the parasitological evidence ( p = 0.038) and a decrease inLeishmania -specific CD4+ lymphocyte proportions (p = 0.035). These results confirm the immunotherapeutic potential of the enriched-Leishmune ® vaccine. The vaccine reduced the clinical symptoms and evidence of parasite, modulating the outcome of the infection and the dog’s potential infectiosity to phlebotomines. The enriched-Leishmune ® vaccine was subjected to a safety analysis and found to be well tolerated and safe |
id |
UFOP_2a49fa171ddf55d1ef235a68c3b16d32 |
---|---|
oai_identifier_str |
oai:localhost:123456789/1042 |
network_acronym_str |
UFOP |
network_name_str |
Repositório Institucional da UFOP |
repository_id_str |
3233 |
spelling |
Santos, Fernanda NunesBorja Cabrera, Gulnara PatriciaMyashiro, L. M.Grechi, JulianaReis, Alexandre BarbosaMoreira, Márcio Antônio BatistelaMartins Filho, Olindo AssisLuvizotto, Maria Cecília RuiMenz, IngridPessôa, L. M.Gonçalves, Pablo RodriguesPalatnik, MarcosSouza, Clarisa Beatriz Palatnik de2012-07-10T14:46:11Z2012-07-10T14:46:11Z2007SANTOS, F. N. et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. Vaccine, v. 25, n. 33, p. 6176-6190, ago. 2007. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0264410X07006810>. Acesso em: 10 jul. 2012.0264410Xhttp://www.repositorio.ufop.br/handle/123456789/1042In order to assess the immunotherapeutic potential on canine visceral leishmaniasis of the Leishmune ® vaccine, formulated with an increased adjuvant concentration (1 mg of saponin rather than 0.5 mg), 24 mongrel dogs were infected with Leishmania (L.) chagasi . The enriched-Leishmune ® vaccine was injected on month 6, 7 and 8 after infection, when animals were seropositive and symptomatic. The control group were injected with a saline solution. Leishmune ® -treated dogs showed significantly higher levels of anti-FML IgG antibodies (ANOVA; p < 0.0001), a higher and stable IgG2 and a decreasing IgG1 response, pointing to a TH1 T cell mediated response. The vaccine had the following effects: it led to more positive delayed type hypersensitivity reactions against Leishmania lysate in vaccinated dogs (75%) than in controls (50%), to a decreased average of CD4+ Leishmania -specific lymphocytes in saline controls (32.13%) that fell outside the 95% confidence interval of the vaccinees (41.62%, CI95% 43.93–49.80) and an increased average of the clinical scores from the saline controls (17.83) that falls outside the 95% confidence interval for the Leishmune ® immunotherapy-treated dogs (15.75, CI95% 13.97–17.53). All dogs that received the vaccine were clustered, and showed lower clinical scores and normal CD4+ counts, whereas 42% of the untreated dogs showed very diminished CD4+ and higher clinical score. The increase in clinical signs of the saline treated group was correlated with an increase in anti-FML antibodies (p < 0.0001), the parasitological evidence ( p = 0.038) and a decrease inLeishmania -specific CD4+ lymphocyte proportions (p = 0.035). These results confirm the immunotherapeutic potential of the enriched-Leishmune ® vaccine. The vaccine reduced the clinical symptoms and evidence of parasite, modulating the outcome of the infection and the dog’s potential infectiosity to phlebotomines. The enriched-Leishmune ® vaccine was subjected to a safety analysis and found to be well tolerated and safeImmunotherapyLeishmuneVaccineCanine visceral leishmaniasisImmunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine.info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleO periódico Vaccine concede permissão para depósito deste artigo no Repositório Institucional da UFOP. Número da licença: 3291410128861.info:eu-repo/semantics/openAccessengreponame:Repositório Institucional da UFOPinstname:Universidade Federal de Ouro Preto (UFOP)instacron:UFOPLICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://www.repositorio.ufop.br/bitstream/123456789/1042/5/license.txt8a4605be74aa9ea9d79846c1fba20a33MD55CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-820325http://www.repositorio.ufop.br/bitstream/123456789/1042/4/license_rdfc7f3e3c064c19e93e905bbb07856484cMD54ORIGINALARTIGO_ImmunotherapyAgainstExperimental.pdfARTIGO_ImmunotherapyAgainstExperimental.pdfapplication/pdf364213http://www.repositorio.ufop.br/bitstream/123456789/1042/1/ARTIGO_ImmunotherapyAgainstExperimental.pdf606a09d592900fcd1eaca57cdb2e8c86MD51123456789/10422019-02-25 13:11:28.423oai:localhost: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Repositório InstitucionalPUBhttp://www.repositorio.ufop.br/oai/requestrepositorio@ufop.edu.bropendoar:32332019-02-25T18:11:28Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP)false |
dc.title.pt_BR.fl_str_mv |
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. |
title |
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. |
spellingShingle |
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. Santos, Fernanda Nunes Immunotherapy Leishmune Vaccine Canine visceral leishmaniasis |
title_short |
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. |
title_full |
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. |
title_fullStr |
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. |
title_full_unstemmed |
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. |
title_sort |
Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. |
author |
Santos, Fernanda Nunes |
author_facet |
Santos, Fernanda Nunes Borja Cabrera, Gulnara Patricia Myashiro, L. M. Grechi, Juliana Reis, Alexandre Barbosa Moreira, Márcio Antônio Batistela Martins Filho, Olindo Assis Luvizotto, Maria Cecília Rui Menz, Ingrid Pessôa, L. M. Gonçalves, Pablo Rodrigues Palatnik, Marcos Souza, Clarisa Beatriz Palatnik de |
author_role |
author |
author2 |
Borja Cabrera, Gulnara Patricia Myashiro, L. M. Grechi, Juliana Reis, Alexandre Barbosa Moreira, Márcio Antônio Batistela Martins Filho, Olindo Assis Luvizotto, Maria Cecília Rui Menz, Ingrid Pessôa, L. M. Gonçalves, Pablo Rodrigues Palatnik, Marcos Souza, Clarisa Beatriz Palatnik de |
author2_role |
author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Santos, Fernanda Nunes Borja Cabrera, Gulnara Patricia Myashiro, L. M. Grechi, Juliana Reis, Alexandre Barbosa Moreira, Márcio Antônio Batistela Martins Filho, Olindo Assis Luvizotto, Maria Cecília Rui Menz, Ingrid Pessôa, L. M. Gonçalves, Pablo Rodrigues Palatnik, Marcos Souza, Clarisa Beatriz Palatnik de |
dc.subject.por.fl_str_mv |
Immunotherapy Leishmune Vaccine Canine visceral leishmaniasis |
topic |
Immunotherapy Leishmune Vaccine Canine visceral leishmaniasis |
description |
In order to assess the immunotherapeutic potential on canine visceral leishmaniasis of the Leishmune ® vaccine, formulated with an increased adjuvant concentration (1 mg of saponin rather than 0.5 mg), 24 mongrel dogs were infected with Leishmania (L.) chagasi . The enriched-Leishmune ® vaccine was injected on month 6, 7 and 8 after infection, when animals were seropositive and symptomatic. The control group were injected with a saline solution. Leishmune ® -treated dogs showed significantly higher levels of anti-FML IgG antibodies (ANOVA; p < 0.0001), a higher and stable IgG2 and a decreasing IgG1 response, pointing to a TH1 T cell mediated response. The vaccine had the following effects: it led to more positive delayed type hypersensitivity reactions against Leishmania lysate in vaccinated dogs (75%) than in controls (50%), to a decreased average of CD4+ Leishmania -specific lymphocytes in saline controls (32.13%) that fell outside the 95% confidence interval of the vaccinees (41.62%, CI95% 43.93–49.80) and an increased average of the clinical scores from the saline controls (17.83) that falls outside the 95% confidence interval for the Leishmune ® immunotherapy-treated dogs (15.75, CI95% 13.97–17.53). All dogs that received the vaccine were clustered, and showed lower clinical scores and normal CD4+ counts, whereas 42% of the untreated dogs showed very diminished CD4+ and higher clinical score. The increase in clinical signs of the saline treated group was correlated with an increase in anti-FML antibodies (p < 0.0001), the parasitological evidence ( p = 0.038) and a decrease inLeishmania -specific CD4+ lymphocyte proportions (p = 0.035). These results confirm the immunotherapeutic potential of the enriched-Leishmune ® vaccine. The vaccine reduced the clinical symptoms and evidence of parasite, modulating the outcome of the infection and the dog’s potential infectiosity to phlebotomines. The enriched-Leishmune ® vaccine was subjected to a safety analysis and found to be well tolerated and safe |
publishDate |
2007 |
dc.date.issued.fl_str_mv |
2007 |
dc.date.accessioned.fl_str_mv |
2012-07-10T14:46:11Z |
dc.date.available.fl_str_mv |
2012-07-10T14:46:11Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
SANTOS, F. N. et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. Vaccine, v. 25, n. 33, p. 6176-6190, ago. 2007. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0264410X07006810>. Acesso em: 10 jul. 2012. |
dc.identifier.uri.fl_str_mv |
http://www.repositorio.ufop.br/handle/123456789/1042 |
dc.identifier.issn.none.fl_str_mv |
0264410X |
identifier_str_mv |
SANTOS, F. N. et al. Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune ® vaccine. Vaccine, v. 25, n. 33, p. 6176-6190, ago. 2007. Disponível em: <https://www.sciencedirect.com/science/article/pii/S0264410X07006810>. Acesso em: 10 jul. 2012. 0264410X |
url |
http://www.repositorio.ufop.br/handle/123456789/1042 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFOP instname:Universidade Federal de Ouro Preto (UFOP) instacron:UFOP |
instname_str |
Universidade Federal de Ouro Preto (UFOP) |
instacron_str |
UFOP |
institution |
UFOP |
reponame_str |
Repositório Institucional da UFOP |
collection |
Repositório Institucional da UFOP |
bitstream.url.fl_str_mv |
http://www.repositorio.ufop.br/bitstream/123456789/1042/5/license.txt http://www.repositorio.ufop.br/bitstream/123456789/1042/4/license_rdf http://www.repositorio.ufop.br/bitstream/123456789/1042/1/ARTIGO_ImmunotherapyAgainstExperimental.pdf |
bitstream.checksum.fl_str_mv |
8a4605be74aa9ea9d79846c1fba20a33 c7f3e3c064c19e93e905bbb07856484c 606a09d592900fcd1eaca57cdb2e8c86 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFOP - Universidade Federal de Ouro Preto (UFOP) |
repository.mail.fl_str_mv |
repositorio@ufop.edu.br |
_version_ |
1793531338911907840 |